REQUEST A DEMO
Total
USD $0.00
Search more companies

Pan-Malayan Pharmaceuticals Pte Ltd (Singapore)

Main Activities: Drugs and Druggists' Sundries Merchant Wholesalers
Secondary Activities: Packaging and Labeling Services
Full name: Pan-Malayan Pharmaceuticals Pte Ltd Profile Updated: March 29, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2022 Available in: English Download a sample report

Primary Business Activity: wholesale of medicinal and pharmaceutical products (western); Secondary Business Activity: packaging activities (primary packaging of health supplement and skin care products)

Headquarters
16 Tai Seng Street, #04-01, Singapore
Singapore; Singapore; Postal Code: 534138

Contact Details: Purchase the Pan-Malayan Pharmaceuticals Pte Ltd report to view the information.

Basic Information
Outstanding Shares:
Purchase the Pan-Malayan Pharmaceuticals Pte Ltd report to view the information.
Financial Auditors:
Purchase the Pan-Malayan Pharmaceuticals Pte Ltd report to view the information.
Incorporation Date:
September 05, 1998
Key Executives
Purchase this report to view the information.
Managing Director
Purchase this report to view the information.
Director
Purchase this report to view the information.
Chief Executive Officer
Ownership Details
Purchase this report to view the information.
100%
Company Performance
Financial values in the chart are available after Pan-Malayan Pharmaceuticals Pte Ltd report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency SGD. Absolute financial data is included in the purchased report.
Net sales revenue
10.04%
Total operating revenue
10.04%
Net Profit (Loss) for the Period
119.29%
Total assets
3.97%
Total equity
53.13%
Net Profit Margin
0.95%
Return on Equity (ROE)
10.47%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?